RIA
ALDX icon

Regal Investment Advisors’s Aldeyra Therapeutics ALDX Stock Holding History

Regal Investment Advisors’s Portfolio ALDX Stock Details ALDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-13,565
Closed -$70.3K – 655
2025
Q4 		$70.3K Buy
13,565
+398
+3% +$2.04K ﹤0.01% 577
2025
Q3 		$68.7K Hold
13,167
– – ﹤0.01% 510
2025
Q2 		$50.4K Hold
13,167
– – ﹤0.01% 477
2025
Q1 		$75.7K Hold
13,167
– – 0.01% 451
2024
Q4 		$65.7K Buy
+13,167
New +$67.6K ﹤0.01% 459

Other funds holding ALDX

KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Regal Investment Advisors's ALDX Position: Q1 2026 in Review

Regal Investment Advisors sold out of Aldeyra Therapeutics (ALDX) in Q1 2026, closing a stake of 13,565 shares — an estimated $70.3K sold.

Regal Investment Advisors first reported a position in ALDX in Q4 2024 and held it in 5 quarters. The position peaked at $75.7K in Q1 2025. 126 funds tracked by Wall St. Rank hold ALDX as of Q1 2026.

  • Regal Investment Advisors reported no remaining Aldeyra Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Regal Investment Advisors sold 13,565 Aldeyra Therapeutics shares in Q1 2026, an estimated $70.3K.
  • Regal Investment Advisors first reported a position in Aldeyra Therapeutics in Q4 2024 and held it in 5 quarters.
  • Regal Investment Advisors's Aldeyra Therapeutics position peaked at $75.7K in Q1 2025.
  • 126 funds tracked by Wall St. Rank held Aldeyra Therapeutics as of Q1 2026.

Based on Regal Investment Advisors's 13F filing for Q1 2026, filed 14 May 2026.